Company intelligence

MRUS

Merus N.V. · NASDAQ · Healthcare

Price$90.00+0.00% · +$0.00

Market cap6.83BEquity value

P / E-17.0Trailing ratio

Volume2.72MLatest session

Market data

MRUS price chart

TradingView

Related signals

1 min delayed

Browse public MRUS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

GMABSep 29, 2025

Genmab Acquires Merus for $8B to Boost Cancer Drug Pipeline

Genmab acquires Merus for $8 billion in cash. Acquisition enhances Genmab's oncology portfolio significantly. Petosemtamab is a late-stage cancer therapy. Strategic growth can positively impact GMAB's market position. Investment reflects confidence in cancer therapeutics market.

View signal analysis

MRUSDec 5, 2024+2.43% since signal

Merus Scores Its First FDA Approval For Lung Cancer Drug

FDA approves MRUS's Bizengri for advanced pancreatic cancer and NSCLC. Bizengri shows 40% ORR in pancreatic adenocarcinoma, 33% in NSCLC. Approval based on eNRGy trial; confirmatory trials needed for continued use. Projected U.S. sales for Bizengri around $16.5 million with $30,000 pricing. MRUS stock fell 3.70% following FDA approval announcement.

View signal analysis

MRUSDec 4, 2024-3.57% since signal

US FDA approves Merus' therapy to treat lung, pancreatic cancers

Merus NV's therapy approved for lung and pancreatic cancers. FDA approval could enhance MRUS competitive position in oncology.

View signal analysis

Research